SANO Stock Overview
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for SANO from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Sanofi Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €103.26 |
| 52 Week High | €106.64 |
| 52 Week Low | €85.21 |
| Beta | 0.46 |
| 1 Month Change | 2.64% |
| 3 Month Change | 11.78% |
| 1 Year Change | 16.38% |
| 3 Year Change | 9.83% |
| 5 Year Change | 23.74% |
| Change since IPO | 21.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| SANO | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | -1.0% | 3.5% | -0.1% |
| 1Y | 16.4% | -0.4% | 13.7% |
Return vs Industry: SANO exceeded the Austrian Pharmaceuticals industry which returned -0.4% over the past year.
Return vs Market: SANO exceeded the Austrian Market which returned 13.7% over the past year.
Price Volatility
| SANO volatility | |
|---|---|
| SANO Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in AT Market | 7.4% |
| 10% least volatile stocks in AT Market | 2.0% |
Stable Share Price: SANO has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: SANO's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 82,878 | Paul Hudson | www.sanofi.com |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines.
Sanofi Fundamentals Summary
| SANO fundamental statistics | |
|---|---|
| Market cap | €130.52b |
| Earnings (TTM) | €5.50b |
| Revenue (TTM) | €44.29b |
23.7x
P/E Ratio2.9x
P/S RatioIs SANO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANO income statement (TTM) | |
|---|---|
| Revenue | €44.29b |
| Cost of Revenue | €13.20b |
| Gross Profit | €31.09b |
| Other Expenses | €25.60b |
| Earnings | €5.50b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 24, 2025
| Earnings per share (EPS) | 4.38 |
| Gross Margin | 70.21% |
| Net Profit Margin | 12.41% |
| Debt/Equity Ratio | 20.6% |
How did SANO perform over the long term?
See historical performance and comparisonDividends
3.8%
Current Dividend Yield89%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 09:41 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sanofi is covered by 60 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamla Singh | AlphaValue |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |